A Phase 3 interventional study of survodutide and Placebo in Obesity, sponsored by Boehringer Ingelheim. Completed at 118 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.
Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing survodutide in Obesity — 4 open to participants now, 7 under way, 3 of them phase 3. survodutide · Obesity.
Among the 22 studies testing survodutide in Obesity, this one is the 3rd largest by enrollment, is one of 4 that started in 2023, is one of 9 in phase 3, and was the 6th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →4 of the 22 studies testing survodutide in Obesity are open now, in 5 countries. Recruiting first, the newest first:
Boehringer Ingelheim · Sites in Germany
Ages 18–65 · Healthy volunteers
Boehringer Ingelheim · Sites in United States, China, Germany and 2 more countries
Ages 18+
Boehringer Ingelheim · Sites in United States
Ages 18+
Boehringer Ingelheim · Sites in United States, United Kingdom
Ages 45–65 · Women only
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 4 started in 2023.
This study's enrollment of 726 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 121 across the 22 interventional studies. Of the 15 that completed or were terminated, 1 (7%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 22 have an industry lead sponsor. The 1 most frequent:
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
32 studies in Obesity by Boehringer Ingelheim: 5 open now, 11 under way, 3 of them phase 3. Of 21 finished, 4 (19%) have results posted.
Among the 32 studies in Obesity by Boehringer Ingelheim, this one is the 3rd largest by enrollment of the 31 interventional ones that give a count, is one of 5 that started in 2023, is one of 10 in phase 3, and was the 12th registered.
Boehringer Ingelheim’s Obesity studies by the year they started, since 2005.
3 of the studies testing survodutide in Obesity that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07768813Boehringer IngelheimA Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or Obesity | 2026-12-08 |
| NCT05202353Boehringer IngelheimA Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver | 2027-01-06 |
| NCT07940244Boehringer IngelheimA Study to Compare How Survodutide is Taken up by the Body When Given in 2 Formulations to People With Overweight or Obesity | 2027-10-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 22 studies testing survodutide in Obesity, from their registry updates:
Among Boehringer Ingelheim’s 32 in Obesity:
This tab as a report to print or save as PDF → With an account.
This study is open to adults who are at least 18 years old and have
People with type 2 diabetes cannot take part in this study. Only people who have previously not managed to lose weight by changing their diet can participate.
The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesity to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly.
Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff.
The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. The results are compared between the groups to see whether the treatment works.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(BMI) ≥30 kg/m\^2 at screening, OR BMI ≥27 kg/m\^2 with the presence of at least one of the obesity-related complications (treated or untreated) e.g,:
Further inclusion criteria apply.
Exclusion Criteria:
Further exclusion criteria apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Combination Product: survodutide
Combination Product: survodutide
Combination Product: Placebo
once weekly subcutaneous injection
Also known as: BI 456906
once weekly subcutaneous injection
Percentage change in body weight from baseline to Week 76
Time frame: Baseline and at Week 76
Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76
Time frame: Baseline and at Week 76
Achievement of body weight reduction ≥10% (yes/no) from baseline to Week 76
Time frame: Baseline and at Week 76
Achievement of body weight reduction ≥15% (yes/no) from baseline to Week 76
Time frame: Baseline and at Week 76
Achievement of body weight reduction ≥20% (yes/no) from baseline to Week 76
Time frame: Baseline and at Week 76
Absolute change from baseline to Week 76 in body weight (kg)
Time frame: Baseline and Week 76
Absolute change from baseline to Week 76 in waist circumference (cm)
Time frame: Baseline and at Week 76
Absolute change from baseline to Week 76 in systolic blood pressure (SBP) (mmHg)
Time frame: Baseline and at Week 76
Absolute change from baseline to Week 76 in "Capacity to Resist" domain score of the Eating Behaviour patient reported outcome (PRO)
"Capacity to Resist" domain score of the Eating Behaviour PRO is ranging between 0 and 24 and a higher score indicates a lower capacity to resist.
Time frame: Baseline and at Week 76
Absolute change from baseline to Week 76 in Eating Behaviour PRO total score
Eating Behaviour PRO total score is ranging between 0 and 48 and a higher score indicates a worse eating behaviour (greater desire to eat and/or lower capacity to resist).
Time frame: Baseline and at Week 76
Absolute change from baseline to Week 76 in body mass index (BMI) (kg/m2)
Time frame: Baseline and at Week 76
Absolute change from baseline to Week 76 in diastolic blood pressure (DBP) (mmHg)
Time frame: Baseline and at Week 76
Absolute change from baseline to Week 76 in glycosylated haemoglobin A1c (HbA1c) (%)
Time frame: Baseline and at Week 76
Absolute change from baseline to Week 76 in HbA1c (mmol/mol)
Time frame: Baseline and at Week 76
Absolute change from baseline to Week 76 in fasting plasma glucose (FPG) (mg/dL)
Time frame: Baseline and at Week 76
Absolute change from baseline to Week 76 in fasting plasma insulin (FPI) (mIU/L)
Time frame: Baseline and at Week 76
Absolute change from baseline to Week 76 in total cholesterol (mg/dL)
Time frame: Baseline and at Week 76
Absolute change from baseline to Week 76 in high density lipoprotein (HDL) cholesterol (mg/dL)
Time frame: Baseline and at Week 76
Absolute change from baseline to Week 76 in low density lipoprotein (LDL) cholesterol (mg/dL)
Time frame: Baseline and at Week 76
Absolute change from baseline to Week 76 in very-low-density lipoprotein (VLDL) cholesterol (mg/dL)
Time frame: Baseline and at Week 76
Absolute change from baseline to Week 76 in triglycerides (mg/dL)
Time frame: Baseline and at Week 76
Absolute change from baseline to Week 76 in free fatty acids (mg/dL)
Time frame: Baseline and at Week 76
Absolute change from baseline to Week 76 in alanine aminotransferase (ALT) (U/L)
Time frame: Baseline and at Week 76
Absolute change from baseline to Week 76 in aspartate aminotransferase (AST) (U/L)
Time frame: Baseline and at Week 76
Absolute change from baseline to Week 76 in total fat volume (L)
Time frame: Baseline and at Week 76
Absolute change from baseline to Week 76 in lean body volume (L)
Time frame: Baseline and at Week 76
Absolute change from baseline to Week 76 in visceral fat volume (L)
Time frame: Baseline and at Week 76
Absolute change from baseline to Week 76 in subcutaneous fat volume (L)
Time frame: Baseline and at Week 76.
Relative change from baseline to Week 76 in total fat volume (%)
Time frame: Baseline and at Week 76
Relative change from baseline to Week 76 in lean body volume (%)
Time frame: Baseline and at Week 76
Relative change from baseline to Week 76 in visceral fat volume (%)
Time frame: Baseline and at Week 76
Relative change from baseline to Week 76 in subcutaneous fat volume (%)
Time frame: Baseline and at Week 76.
Relative change from baseline to Week 76 in liver fat content (%)
Time frame: Baseline and at Week 76
Showing the first 100 of 118 sites across 14 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: After structured results have been posted, all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.
Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'.For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com
Ran from Nov 2023 to primary completion in Dec 2025, 24 months.
Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 24 months is above that.
Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Survodutide